Literature DB >> 1281336

Complement receptor type 2 mediates infection of the human CD4-negative Raji B-cell line with opsonized HIV.

V Boyer1, C Delibrias, N Noraz, E Fischer, M D Kazatchkine, C Desgranges.   

Abstract

Opsonization of the HTLV-RF and HTLV-IIIB strains of HIV-1 with normal human HIV seronegative serum under conditions that allow complement activation resulted in the productive infection of cells of the Raji B lymphoblastoid cell line. Under the same experimental conditions, no infection of Raji cells was observed with unopsonized virus. Infection of Raji cells with complement-opsonized HIV-1 was totally suppressed by preblocking the function of CR2 (the C3dg receptor, CD21) on the cells with a monoclonal anti-CR2 antibody cross-linked with rabbit F(ab')2 anti-mouse immunoglobulin antibodies. Infection of Raji cells occurred independently of CD4 since the cells lacked the expression of CD4 antigen and of CD4 transcripts. Thus, Raji cells may be infected with complement-opsonized HIV independently of CD4 and in the absence of antibodies. By mediating and/or enhancing HIV infection, complement and complement receptors contribute to extend the range of target cells to the virus and may increase infection in patients with a low viral load.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1281336     DOI: 10.1111/j.1365-3083.1992.tb03150.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  7 in total

1.  Complement component 3 interactions with coxsackievirus B3 capsid proteins: innate immunity and the rapid formation of splenic antiviral germinal centers.

Authors:  D R Anderson; C M Carthy; J E Wilson; D Yang; D V Devine; B M McManus
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

Review 2.  Role of complement and Fc receptors in the pathogenesis of HIV-1 infection.

Authors:  D C Montefiori
Journal:  Springer Semin Immunopathol       Date:  1997

3.  Engineering of recombinant soluble CD46: an inhibitor of complement activation.

Authors:  D Christiansen; J Milland; B R Thorley; I F McKenzie; P L Mottram; L J Purcell; B E Loveland
Journal:  Immunology       Date:  1996-03       Impact factor: 7.397

4.  Studies on the mechanism of complement-mediated inhibition of antibody binding to HIV gp41.

Authors:  T Hidvégi; Z Prohászka; E Ujhelyi; N M Thielens; M P Dierich; H Hampl; G Arlaud; K Nagy; G Füst
Journal:  Clin Exp Immunol       Date:  1993-12       Impact factor: 4.330

Review 5.  Enhancing role of complement in HIV infection.

Authors:  A Mouhoub; N Thieblemont; C Delibrias; E Fischer; M D Kazatchkine
Journal:  Clin Exp Immunol       Date:  1994-08       Impact factor: 4.330

6.  Antibody-dependent enhancement of hepatitis C virus infection.

Authors:  Keith Meyer; Malika Ait-Goughoulte; Zhen-Yong Keck; Steven Foung; Ranjit Ray
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

Review 7.  The antiviral activity of antibodies in vitro and in vivo.

Authors:  P W Parren; D R Burton
Journal:  Adv Immunol       Date:  2001       Impact factor: 3.543

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.